Oxford Cannabinoid Technologies Holdings Plc Equity Research & Stock Reports

Equity Research, Broker Reports, and media content on Oxford Cannabinoid Technologies Holdings Plc

Access the latest forecasts, broker valuations, multiples, and video content from the city about Oxford Cannabinoid Technologies Holdings Plc
See live updates from analysts, company announcements, and other news in a personalised/single dashboard

25 Mar 24

Oxford Cannabinoid Technologies Holdings - February 2024 update

22 Mar 24

Oxford Cannabinoid Technologies Holdings - Elevator Pitch

05 Feb 24

Oxford Cannabinoid Technologies - Early signs of revival in clinical activity

Oxford Cannabinoid Technologies (OCT) has announced its H124 results (to end-October 2023), an eventful period for the company, marked by successful clinical progression of lead asset OCT461201, albeit with some funding challenges. Key highlights included the initiation and subsequent positive safety data from OCT’s first Phase I clinical trial (Programme 1) and a foray into oncology (Programme 4). Tight funding conditions halted subsequent clinical progress, although the recently announced £1.3

Companies: Oxford Cannabinoid Technologies Holdings Plc

Edison

17 Jan 24

Proactive research analyst on Oxford Cannabinoid Technologies' plans for 2024

20 Nov 23

Oxford Cannabinoid Technologies strengthens board with CMO Dr. Tim Corn

12 Oct 23

Oxford Cannabinoid Technologies - Poised to progress to Phase II pending raise

Oxford Cannabinoid Technologies (OCT) has announced the completion of its Phase I trial, a single ascending dose study for its lead drug candidate, OCT461201. The results of the Phase I study demonstrated safety and tolerability across the tested doses and OCT will prepare to proceed to Phase II provided it is able to raise funds in a timely manner. We continue to expect the subsequent Phase II trial to be conducted in patients with neuropathic pain associated with chemotherapy-induced periphera

Companies: Oxford Cannabinoid Technologies Holdings Plc

Edison

10 Oct 23

Oxford Cannabinoid Technologies CEO says objective "absolutely met" in lead asset trial

25 Sep 23

Oxford Cannabinoid Technologies reports no adverse events in OCT461201 trial

12 Sep 23

Oxford Cannabinoid Technologies - Clinical headway rests on funding

Oxford Cannabinoid Technologies (OCT) has shared its FY23 results and summarised its ongoing activities. OCT completed preclinical research for OCT461201 (programme 1) and in July 2023 the first healthy volunteer was dosed in the Phase I safety study; results are expected in Q3 CY23. Management believes this programme will be Phase II ready by Q4 CY23, and plans to target neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) and visceral pain in irritable bowel syndr

Companies: Oxford Cannabinoid Technologies Holdings Plc

Edison

31 Aug 23

Oxford Cannabinoid Technologies in a "comfortable position" ahead of Phase 1 results release

27 Jul 23

OCT enters clinical development with 201

Oxford Cannabinoid Technologies (OCT) develops a range of cannabinoid-derived pharmaceuticals. The key news is that the Phase 1 dose and safety study of its lead indication OCT461201 (“201”) with up to 32 volunteers has started.The phase I should be followed by a phase II in patients with establish

Companies: Oxford Cannabinoid Technologies Holdings Plc

Proactive

17 Jul 23

Oxford Cannabinoid's breakthrough oral immunotherapy: “The initial data demonstrates excellent potential”

17 Jul 23

Oxford Cannabinoid Technologies - A move away from generic pain treatment

Oxford Cannabinoid Technologies (OCT) is focused on developing cannabinoid medicines for the treatment of pain and other indications. Lead asset OCT461201 is a synthetic, endocannabinoid system-targeting new chemical entity (NCE) being developed for the treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy (CIPN) and visceral pain in irritable bowel syndrome (IBS). Preclinical studies have demonstrated positive early signals of efficacy in pain indications and

Companies: Oxford Cannabinoid Technologies Holdings Plc

Edison

24 May 23

Oxford Cannabinoid Technologies: Phase 1 approval for lead chronic pain drug

24 May 23

Oxford Cannabinoid Technologies: Phase 1 approval for lead chronic pain drug - Analyst Interview